| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/13543776.2010.533171 |
| P698 | PubMed publication ID | 21083519 |
| P2093 | author name string | Bryan Goodwin | |
| Philip A Carpino | |||
| P2860 | cites work | Role of AMP-activated protein kinase in mechanism of metformin action | Q22241898 |
| Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal | Q24529830 | ||
| Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats | Q24563606 | ||
| Differential expression and regulation of the glucokinase gene in liver and islets of Langerhans | Q24605470 | ||
| Gene knockout of Acc2 has little effect on body weight, fat mass, or food intake | Q24622227 | ||
| The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity | Q24624806 | ||
| Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets | Q24683319 | ||
| Stearoyl-CoA desaturase 1 deficiency elevates insulin-signaling components and down-regulates protein-tyrosine phosphatase 1B in muscle | Q24685655 | ||
| The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids | Q27863758 | ||
| Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. | Q27863762 | ||
| GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. | Q27865189 | ||
| Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice | Q27865234 | ||
| Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme | Q28115363 | ||
| Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria | Q28184005 | ||
| The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus | Q28190307 | ||
| Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2 | Q28209958 | ||
| Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria | Q28211392 | ||
| Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2) | Q28215167 | ||
| Does central obesity reflect "Cushing's disease of the omentum"? | Q28236784 | ||
| GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis | Q28237976 | ||
| GPR119 agonists for the treatment of type 2 diabetes | Q28259606 | ||
| How many drug targets are there? | Q28276660 | ||
| Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119 | Q28290694 | ||
| Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents | Q28300398 | ||
| Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells | Q28304006 | ||
| Glucose and fat metabolism in adipose tissue of acetyl-CoA carboxylase 2 knockout mice | Q28506934 | ||
| Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor | Q28509942 | ||
| Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals | Q28568642 | ||
| Glucokinase is the likely mediator of glucosensing in both glucose-excited and glucose-inhibited central neurons | Q28570095 | ||
| SIRT1 transgenic mice show phenotypes resembling calorie restriction | Q29301793 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes | Q30392597 | ||
| Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity | Q30433606 | ||
| Cell-specific roles of glucokinase in glucose homeostasis. | Q32120158 | ||
| Tissue-specific dysregulation of cortisol metabolism in human obesity | Q32132870 | ||
| It's not how fat you are, it's what you do with it that counts | Q33371764 | ||
| Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice | Q33782682 | ||
| Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 | Q33880303 | ||
| Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity | Q33960868 | ||
| A transgenic model of visceral obesity and the metabolic syndrome | Q34104691 | ||
| The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose | Q34121476 | ||
| Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level | Q34575066 | ||
| Glucose sensing in L cells: a primary cell study | Q34890796 | ||
| Assessing the potential of glucokinase activators in diabetes therapy | Q34976240 | ||
| Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis | Q35039363 | ||
| Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose | Q35184196 | ||
| Phlorizin: a review | Q35995949 | ||
| Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity | Q36082167 | ||
| Regulation of plasma triglycerides in insulin resistance and diabetes | Q36144459 | ||
| Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice | Q36807640 | ||
| 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress | Q36833926 | ||
| The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. | Q36842612 | ||
| Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver | Q37023053 | ||
| Economic costs of diabetes in the U.S. In 2007. | Q37097601 | ||
| GPR40: good cop, bad cop? | Q37163504 | ||
| Glucokinase and molecular aspects of liver glycogen metabolism | Q37225692 | ||
| The long-chain fatty acid receptor, GPR40, and glucolipotoxicity: investigations using GPR40-knockout mice | Q37269531 | ||
| AMPK: an emerging drug target for diabetes and the metabolic syndrome | Q37471010 | ||
| Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes | Q37481309 | ||
| Review of recent acetyl-CoA carboxylase inhibitor patents: mid-2007-2008. | Q37529806 | ||
| Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia | Q37605708 | ||
| 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation | Q37616950 | ||
| Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents | Q37620374 | ||
| Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus | Q37703693 | ||
| Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. | Q37709188 | ||
| Insulin resistance in nonalcoholic fatty liver disease. | Q37725021 | ||
| 17beta-Hydroxysteroid dehydrogenase inhibitors: a patent review | Q37774374 | ||
| Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6. | Q39756567 | ||
| Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules | Q40279477 | ||
| Impact of mitochondrial reactive oxygen species and apoptosis signal-regulating kinase 1 on insulin signaling | Q40286568 | ||
| Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion | Q41918359 | ||
| Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. | Q42033681 | ||
| GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell | Q42146257 | ||
| Stearoyl-CoA desaturase 1 deficiency increases insulin signaling and glycogen accumulation in brown adipose tissue | Q42469429 | ||
| Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study | Q42925831 | ||
| Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus | Q43199877 | ||
| Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438). | Q43224856 | ||
| Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice | Q43730363 | ||
| Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice | Q44219623 | ||
| Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity | Q44238649 | ||
| Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. | Q44273298 | ||
| Allosteric activators of glucokinase: potential role in diabetes therapy | Q44517691 | ||
| Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains | Q44576264 | ||
| The mechanism by which rat liver glucokinase is inhibited by the regulatory protein | Q44576851 | ||
| Lack of stearoyl-CoA desaturase 1 upregulates basal thermogenesis but causes hypothermia in a cold environment | Q44947202 | ||
| Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin | Q45105936 | ||
| Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats | Q45763147 | ||
| The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis | Q46132296 | ||
| Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models | Q46516165 | ||
| The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse | Q46626401 | ||
| A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release | Q46665845 | ||
| Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans | Q46744686 | ||
| GPR40 is expressed in glucagon producing cells and affects glucagon secretion. | Q51800702 | ||
| Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family | Q56592584 | ||
| 11-Beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in Type 2 diabetes mellitus and obesity | Q58896395 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1627-1651 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Expert Opinion on Therapeutic Patents | Q5421213 |
| P1476 | title | Diabetes area participation analysis: a review of companies and targets described in the 2008 - 2010 patent literature | |
| P478 | volume | 20 |
| Q27676986 | 3'-axial CH2 OH substitution on glucopyranose does not increase glycogen phosphorylase inhibitory potency. QM/MM-PBSA calculations suggest why |
| Q37884060 | A survey of small molecule glucagon receptor antagonists from recent patents (2006 - 2010). |
| Q34251407 | Action of molecular switches in GPCRs--theoretical and experimental studies. |
| Q47111998 | An Integrated Computational Approach for Plant-Based Protein Tyrosine Phosphatase Non-Receptor Type 1 Inhibitors |
| Q46002723 | Building structure-activity insights through patent mining. |
| Q26765392 | Computational prediction of formulation strategies for beyond-rule-of-5 compounds |
| Q28484141 | Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach |
| Q47838652 | Diabetes area patent participation analysis - part II: years 2011-2016. |
| Q39771912 | Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics |
| Q33630584 | GPR119 Modulators for the Treatment of Diabetes, Obesity, and Related Diseases: Patent Highlight |
| Q47739754 | Identification of novel PPARα/γ dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations |
| Q38080471 | Latest research and development trends in non-insulin anti-diabetics |
| Q26824024 | MicroRNAs as pharmacological targets in diabetes |
| Q64012993 | Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development |
| Q39636097 | Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology |
| Q38001579 | Recent discovery of plant-derived anti-diabetic natural products |
| Q36417959 | Sterculic Oil, a Natural SCD1 Inhibitor, Improves Glucose Tolerance in Obese ob/ob Mice |
| Q51344866 | Sterculic oil, a natural inhibitor of SCD1, improves the metabolic state of obese OLETF rats. |
| Q95852906 | The Glucose Lowering Effect of Zornia gibbosa Span Extracts in Diabetic Rats |
| Q36399676 | The Hypothalamic-Pituitary-Adrenal Axis, Obesity, and Chronic Stress Exposure: Sleep and the HPA Axis in Obesity |
| Q26865958 | The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy |
| Q36174164 | Transgenic mouse models resistant to diet-induced metabolic disease: is energy balance the key? |
Search more.